MA55040A - Utilisation d'agonistes de ppar-delta dans le traitement de la myopathie mitochondriale - Google Patents

Utilisation d'agonistes de ppar-delta dans le traitement de la myopathie mitochondriale

Info

Publication number
MA55040A
MA55040A MA055040A MA55040A MA55040A MA 55040 A MA55040 A MA 55040A MA 055040 A MA055040 A MA 055040A MA 55040 A MA55040 A MA 55040A MA 55040 A MA55040 A MA 55040A
Authority
MA
Morocco
Prior art keywords
ppar
treatment
mitochondrial myopathy
delta agonists
agonists
Prior art date
Application number
MA055040A
Other languages
English (en)
Inventor
Alex Dorenbaum
Colin O'carroll
Niall O'donnell
Lynn Purkins
Original Assignee
Reneo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneo Pharmaceuticals Inc filed Critical Reneo Pharmaceuticals Inc
Publication of MA55040A publication Critical patent/MA55040A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055040A 2019-02-20 2020-02-20 Utilisation d'agonistes de ppar-delta dans le traitement de la myopathie mitochondriale MA55040A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962808137P 2019-02-20 2019-02-20

Publications (1)

Publication Number Publication Date
MA55040A true MA55040A (fr) 2021-12-29

Family

ID=72144463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055040A MA55040A (fr) 2019-02-20 2020-02-20 Utilisation d'agonistes de ppar-delta dans le traitement de la myopathie mitochondriale

Country Status (14)

Country Link
US (1) US20220117972A1 (fr)
EP (1) EP3927718A4 (fr)
JP (1) JP2022523645A (fr)
KR (1) KR20210134348A (fr)
CN (1) CN113710683A (fr)
AU (1) AU2020224129A1 (fr)
BR (1) BR112021016142A2 (fr)
CA (1) CA3127470A1 (fr)
IL (1) IL285500A (fr)
MA (1) MA55040A (fr)
MX (1) MX2021009938A (fr)
SG (1) SG11202108926YA (fr)
TW (1) TW202045152A (fr)
WO (1) WO2020172421A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009252A (es) * 2019-02-04 2021-10-01 Reneo Pharmaceuticals Inc Uso de un agonista de ppar-delta en el tratamiento de trastornos de oxidacion de acidos grasos (faod).
EP4085906A1 (fr) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprenant un modulateur de ppar et un dérivé d'urolithine et ses utilisations
CA3221429A1 (fr) * 2021-06-02 2022-12-08 Astellas Pharma Inc. Procedes d'utilisation de composes agonistes ppar et compositions pharmaceutiques associees
WO2023282306A1 (fr) * 2021-07-06 2023-01-12 国立大学法人東京大学 COMPOSITION PHARMACEUTIQUE DE TRAITEMENT OU DE PRÉVENTION D'UNE MALADIE ASSOCIÉE À LA RÉDUCTION OU AU DÉFAUT DE MODIFICATION τM5U
WO2023147309A1 (fr) * 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie
CN114457114B (zh) * 2022-03-07 2023-07-14 中国人民解放军空军军医大学 一种Fars2基因条件性敲除动物模型的构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776916B2 (en) * 2004-04-28 2010-08-17 The Uab Research Foundation Nitrated lipids and methods of making and using thereof
EP2386540A1 (fr) * 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Nouveaux composés, leur utilisation et préparation
EP3043789B1 (fr) * 2013-09-09 2020-07-08 vTv Therapeutics LLC Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire
WO2016057656A1 (fr) * 2014-10-08 2016-04-14 Mitobridge, Inc. Agonistes ppar-delta destinés à être utilisés pour le traitement d'affections mitochondriales, vasculaires, musculaires et démyélynisantes
MX2021009252A (es) * 2019-02-04 2021-10-01 Reneo Pharmaceuticals Inc Uso de un agonista de ppar-delta en el tratamiento de trastornos de oxidacion de acidos grasos (faod).

Also Published As

Publication number Publication date
AU2020224129A1 (en) 2021-10-07
WO2020172421A1 (fr) 2020-08-27
TW202045152A (zh) 2020-12-16
IL285500A (en) 2021-09-30
BR112021016142A2 (pt) 2022-01-04
EP3927718A1 (fr) 2021-12-29
EP3927718A4 (fr) 2022-12-07
SG11202108926YA (en) 2021-09-29
MX2021009938A (es) 2021-10-13
CA3127470A1 (fr) 2020-08-27
CN113710683A (zh) 2021-11-26
KR20210134348A (ko) 2021-11-09
US20220117972A1 (en) 2022-04-21
JP2022523645A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
MA55040A (fr) Utilisation d'agonistes de ppar-delta dans le traitement de la myopathie mitochondriale
MA52575A (fr) Pansement pour le traitement de la peau endommagée
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA51620A (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
MA52910A (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
MA41818A (fr) Timbre à micro-aiguilles pour administration d'un principe actif à la peau
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
IL279810A (en) Heteroaryl-converted sulfonamide compounds and their use as medicinal agents
FR3061017B1 (fr) Composition cosmetique comprenant de la gelee royale d'abeille noire d'ouessant
MA50441A (fr) Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
MA49017A (fr) Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
MA53501A (fr) Inhibiteurs de pde9 pour le traitement de la drépanocytose
MA53924A (fr) Modulateurs de l'expression d'apol1
MA43730A (fr) Malassezine et analogues correspondants en tant qu'agents d'éclaircissement de la peau
FR3055548B1 (fr) Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
FR3025424B1 (fr) Principe actif obtenu a partir de calendula officinalis et utilisation dans la prevention et le traitement de manifestations cutanees dues a un dereglement de l'epigenome dans les cellules de la peau
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
FR3079749B1 (fr) Utilisation d'un peptide pour un traitement de l'epiderme
ITUB20160828A1 (it) Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro